Theratechnologies (TSX:TH) ROE % Adjusted to Book Value : Negative Equity% (As of Aug. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies ROE % Adjusted to Book Value?

Theratechnologies's ROE % for the quarter that ended in Aug. 2024 was Negative Equity. Theratechnologies's PB Ratio for the quarter that ended in Aug. 2024 was N/A. Theratechnologies's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2024 was Negative Equity.

Theratechnologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Theratechnologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies ROE % Adjusted to Book Value Chart

Theratechnologies Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-4.40

-2.92

-16.76

Theratechnologies Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	Negative Equity	Negative Equity

Competitive Comparison of Theratechnologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Theratechnologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theratechnologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Theratechnologies's ROE % Adjusted to Book Value falls into.

Theratechnologies ROE % Adjusted to Book Value Calculation

Theratechnologies's ROE % Adjusted to Book Value for the fiscal year that ended in Nov. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Theratechnologies's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

Theratechnologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Theratechnologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany TQ80:Germany

Address

2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Executives

Dale Weil	Director
Joseph Arena	Director
Philippe Dubuc	Senior Officer
Gérald A. Lacoste	Director
Paul Lévesque	Senior Officer
Andrew Molson	Director
Dawn Svoronos	Director
John Leasure	Senior Officer
Alain Trudeau	Director
Sheila Frame	Director
Gary Peter Littlejohn	Director
Marie-noël Colussi	Senior Officer
Jovan Antunovic	Senior Officer
Christian Marsolais	Senior Officer
Jocelyn Lafond	Senior Officer